Thomas Hawthorne

TL;DR: It is concluded that, as a single agent, 3BNC117 is safe and effective in reducing HIV-1 viraemia, and that immunotherapy should be explored as a new modality for HIV- 1 prevention, therapy and cure.

TL;DR: It is concluded that administration of 3BNC117 exerts strong selective pressure on HIV-1 emerging from latent reservoirs during ATI in humans, suggesting failure to escape over a period of 9-19 weeks.

TL;DR: Glembatumumab vedotin was well tolerated as compared with IC chemotherapy (less hematologic toxicity; more rash, pruritus, neuropathy, and alopecia), and activity may be enhanced in patients with gpNMB-overexpressing tumors and/or TNBC.

TL;DR: Dose escalation of varlilumab to 10 mg/kg was well tolerated without identification of a maximum tolerated dose and evidence of biologic activity consistent with CD27 stimulation-chemokine induction, T-cell stimulation, regulatory T cell depletion-was observed at all dose levels.

TL;DR: Glembatumumab vedotin is active in advanced melanoma and was associated with a promising ORR and was generally well tolerated.